MiDROPS® Achieves Clinical Safety and Efficacy Milestone
EyeCRO is thrilled to announce the first clinical application of our groundbreaking MiDROPS® technology.
EyeCRO joins Novo Nordisk, Novartis, Sanofi, Merck KGaA Darmstadt Germany, Lundbeck, and Leo Pharma to prioritize animal welfare in scientific research by signing the Marseille Declaration
“Toward enhancing ethical practices in scientific research, EyeCRO has joined several industry-leading companies to sign the “Marseille Declaration”, the first joint pharmaceutical industry declaration on animal housing and use.” Click here to read the full press release
EyeCRO scientist contributes to a paper published in Experimental Eye Research
EyeCRO scientist Jarrod Harman contributed to a paper focused on X-linked juvenile retinoschisis published in Experimental Eye Research. This paper expands the mechanistic understanding of XLRS. Read the full paper here https://www.sciencedirect.com/science/article/pii/S0014483523002129?dgcid=coauthor
EyeCRO scientists contribute to paper published in Biology
Therapeutic Effects of Fenofibrate Nano-Emulsion Eye Drops on Retinal Vascular Leakage and Neovascularization Click here to read more
EyeCRO scientists contribute to study published in Experimental Eye Research
Intravitreal administration of small molecule read-through agents demonstrate functional activity in a nonsense mutation mouse model. Click here to read more
InMed Licenses MiDROPS® Delivery Technology from EyeCRO for the Delivery of Therapeutic Cannabinoids
Inmed Pharmaceuticals Inc. (NASD: INM) has secured a worldwide license to formulate any cannabinoid molecule using MiDROPS® for ophthalmic instillation. Click here to read the full press release.
EyeCRO scientists contribute to study published in Nature
“Researchers have discovered a technique for directly reprogramming skin cells into light-sensing rod photoreceptors used for vision. The lab-made rods enabled blind mice to detect light after the cells were transplanted into the animals’ eyes. The work, funded by the National Eye Institute (NEI), published April 15 in Nature.” (Click here to read rest of article)
Is Treat-and-Extend Truly Effective for Diabetic Macular Edema?
“Anti-vascular endothelial growth factor (anti-VEGF) medications have a proven track record in treating diabetic macular edema (DME). However, researchers continue to investigate whether these medications can be made more efficient and cost-effective.” “Both the RETAIN[1] and REACT[2] studies showed that treat-and-extend regimens for ranibizumab were efficacious for DME. Further support was provided by the TREX-DME study, the first prospective, randomized controlled…
New Age-Related Macular Degeneration Common in Untreated Fellow Eyes
“NEW YORK (Reuters Health) – New age-related macular degeneration (AMD) develops in about a quarter of fellow eyes to those treated for neovascular AMD with intravitreal anti-VEGF agents, according to a post hoc analysis of the VIEW 1 and VIEW 2 studies.” “The high risk for fellow eye conversion in patients with neovascular AMD in…
Double-Barreled Biologic for Diabetic Retinopathy Emerging
CHICAGO — Investigators searching for new ways to manage diabetic macular edema are targeting pathways beyond vascular endothelial growth factor (VEGF). Phase 2 results from the BOULEVARD trial (NCT02699450), which is comparing faricimab, the first biologic to target both the Ang-2 and VEGF pathways, with ranibizumab, will be presented at the American Society of Retina Specialists (ASRS) 2019 Annual…